ERBB2 and triple-negative breast carcinoma: Triple-negative breast cancer (TNBC) such as MDA-MB-231 is responsible for more than 15–20% of cases, and MDA-MB-23 is typically more aggressive and challenging to treat and more likely to recur compared to HER2+ breast cancer because of the lack of ER, PR, and HER2.